In phase I and I/IIa clinical trials for HNSCC, preliminary results indicate that relatlimab, whether used as monotherapy or in combination with anti-PD-1, exhibits good tolerability, efficacy, and controllable toxicity characteristics. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.